ArticlePloS one2026
Clinical utility of combining the C-reactive protein-to-albumin ratio and systemic immune-inflammation index for prognostic assessment in metastatic renal cell carcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation-based biomarkers may refine prognostic stratification in patients with metastatic renal cell carcinoma (mRCC). This study evaluated the prognostic value of the pretreatment C-reactive protein-to-albumin ratio (CAR) and systemic immune-inflammation index (SII) in patients with mRCC receiving first-line systemic therapy.
methodsWe retrospectively analyzed 117 patients who received first-line systemic therapy between January 2001 and April 2022. Pretreatment CAR and SII were evaluated as readily available blood-based inflammatory biomarkers. Overall survival (OS) was defined as the primary outcome, and progression-free survival (PFS) was defined as the secondary outcome. Exploratory cutoffs were CAR 0.0731 and SII 533.81.
resultsHigh CAR and high SII were independently associated with shorter OS after adjustment for IMDC risk classification and nephrectomy status. The adjusted HRs were 2.36 for high CAR (95% CI, 1.30-4.27; p = 0.005) and 2.58 for high SII (95% CI, 1.42-4.69; p = 0.002). Patients with concurrent elevation of both CAR and SII had the shortest OS compared with those with neither marker elevated (HR, 6.39; 95% CI, 2.76-14.77; p < 0.001). Adding CAR and SII to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) improved the optimism-corrected C-index for OS from 0.641 to 0.733.
conclusionsPretreatment CAR and SII were associated with OS in patients with mRCC receiving first-line systemic therapy. These readily available biomarkers may help refine OS risk assessment when used alongside established clinical factors, but external validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.